ArticleCancer prevention research (Philadelphia, Pa.)2021
Uptake of Genetic Testing Among Patients with Cancer At Risk for Lynch Syndrome in the National Health Interview Survey.
Article in Cancer prevention research (Philadelphia, Pa.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Bridging the implementation gap in hereditary cancer care for prostate cancer: a narrative review and Japanese environmental scan.International journal of clinical oncology · 2026Review
- Cancer genetic testing uptake in the primary care setting: Patient perspectives on barriers and facilitators throughout the testing process.Journal of genetic counseling · 2026Article
- Patients' and family members' experiences with cascade testing for Lynch syndrome in the USA: a qualitative interview study.Journal of community genetics · 2026Article
- Next-Generation Sequencing-Based Detection ofGenes · 2026Article
- Rectifying referrals: genetics testing is underutilized in rectal cancer patient care.Proceedings (Baylor University. Medical Center) · 2026Article
- Survivors' Responses to an Online Intervention to Promote Discussions of Cancer Genetic Risk with Blood Relatives.Public health genomics · 2026Article
- Article
- Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing.Communications medicine · 2024Article
- Modifiable risk factors for cancer among people with lynch syndrome: an international, cross-sectional survey.Hereditary cancer in clinical practice · 2024Article
- Psychosocial factors impacting barriers and motivators to cancer genetic testing.Cancer medicine · 2023Article
- Genetic Testing and/or Counseling for Colorectal Cancer by Health Insurance Type.Journal of personalized medicine · 2022Article
- Article
- Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Lynch syndrome is the most common inherited cancer syndrome that increases the risk of developing colorectal and endometrial cancer. Universal screening guidelines were first recommended by the Centers for Disease Control and Prevention (CDC) in 2009 and are updated annually by multiple societies. Therefore, one would expect genetic testing rates to increase over time. But testing remains underutilized among those with colorectal or endometrial cancer, even though early detection can improve prognosis and survival rates. In this study, we aimed to understand differences in genetic testing uptake among those with colorectal cancer or endometrial cancer from 2005, 2010, 2015, using data from the National Health Interview Survey (NHIS). We examined genetic testing uptake across cancer-type, age (≤50 or ≥51), sex, race, insurance, and education using a χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.